GL Capital

What GL Capital does

GL Capital (德福资本) is a Greater China-focused, healthcare-specialized private equity investment management firm founded in 2010 by Jeffrey Li (李振福), former President of Novartis China. The firm executes buyouts and significant minority investments across six healthcare sub-sectors: pharmaceuticals and biotechnology (specialty pharma, branded OTCs, innovative drugs), medical devices and laboratory consumables, healthcare services (rehabilitation platforms, specialty hospitals and clinics), in-vitro diagnostics (key raw materials and reagents), CXO (CRO and CDMO), and other areas including nutritional supplements, animal health, specialty APIs, and advanced wound care. As of August 30, 2025, GL Capital manages approximately USD 3.9 billion in healthcare assets across 99 portfolio companies, with a core team of 14 and offices in Beijing (headquarters), Guangzhou, Hong Kong, and London.

The firm's product platform combines capital deployment with multi-faceted portfolio value-added services spanning growth strategy, financial compliance, government affairs, operational efficiency, business management, capital management, talent development, and M&A advisory. A dedicated ESG investment advisory service, formalized by UNPRI signatory status since 2022, sits alongside the core investment offering. Notable portfolio outcomes include an average revenue growth rate of 30.4% and profit growth of 31.4% across invested companies, a 25% portfolio IPO rate, a 6.5-year average investment period, and the $8.4 billion Bristol Myers Squibb strategic licensing agreement for portfolio company SystImmune's (百利天恒) BL-B01D1 drug.

Revenue is generated through traditional private equity mechanics: management fees on committed or invested AUM and carried interest on successful exits. LPs comprise prestigious domestic and overseas insurers, funds of funds (FoFs), and other institutional players. The firm has achieved 1.3x Gross DPI across all USD funds with approximately 1% realized losses, 5.1x gross MOIC across realized buyouts, and 9 buyouts completed including 5 exits. GP commitment stands at USD 193 million (~5% of total AUM), indicating strong principal alignment with LPs.

Name

GL Capital

Legal name

GL Capital

Website

https://gl-investment.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

GL Capital (德福资本) is a Greater China-focused private equity firm founded in 2010 that specializes in buyout and significant minority investments across six healthcare sub-sectors, managing approximately USD 3.9 billion in assets across 99 portfolio companies for institutional LPs.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYBPAHAOAE

Equity Capital Advisory (Private Equity Placements, Growth Capital)

Business & Public Services/Professional Services (Legal, Accounting, Consulting)/M&A, Transaction & Restructuring Advisory

SECONDARYFSAAALAG

Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure)

Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing

Keywords

• Healthcare private equity
• Buyout investments
• Growth capital
• Fund management
• Portfolio management

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Infrastructure, Technology or R&D

Revenue model

1. Management fees and carried interest: As a private equity firm, GL Capital generates revenue through management fees on AUM and carried interest (performance fees) from successful exits of portfolio companies. The firm manages USD 3.9 billion in healthcare assets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

GL Capital manages healthcare-focused private equity funds offering buyout and significant minority investments across six sub-sectors: pharmaceuticals and biotechnology, medical devices, healthcare services, IVD, CXO, and other healthcare adjacencies. With approximately USD 3.9 billion AUM across 99 portfolio companies, the firm combines capital investment with operational value-added services including growth strategy, financial compliance, government affairs, talent development, and M&A advisory. ESG/UNPRI-aligned responsible investment practices complement the core offering.

Product overview

GL Capital operates as a unified investment platform offering healthcare-focused private equity fund management with approximately $3.9 billion in AUM, managing 99 portfolio companies across pharmaceuticals, medical devices, healthcare services, IVD, and CXO subsectors. The core offering combines capital investment with comprehensive value-added services including growth strategy, financial compliance, government affairs, operational efficiency, business management, capital management, talent development, and M&A advisory. The platform is further supported by ESG investment advisory services guided by UNPRI principles since 2022, positioning the firm as a strategic partner rather than a passive financial investor.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Investment Fund Management Buyout and significant minority investment funds focused exclusively on Greater China healthcare, with sub-sector coverage of pharmaceuticals & biotechnology, medical devices, healthcare services, IVD, CXO, and other healthcare adjacencies. Offered to domestic and overseas institutional LPs including insurers and FoFs.
• Portfolio Company Value-Added Services Multi-faceted support to portfolio companies including growth strategy, financial compliance, government affairs, operational efficiency, business management, capital management, talent development, and M&A advisory. Aimed at C-suite and founders of healthcare portfolio companies to drive the firm's reported 30.4% average revenue growth and 31.4% average profit growth.
• ESG Investment Advisory Responsible investment services guided by ESG and sustainability principles under the UNPRI framework, applied to GL Capital's investment decisions and portfolio company oversight to enhance ESG performance, manage environmental footprint, foster inclusive workplace, and build greener communities.

Quantifiable outcome

• 30.4% average revenue growth rate of invested companies
• +7 more outcomes

Named customers20 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• UNPRI (United Nations Principles for Responsible Investment)coreStrategic or Co-development Partner · 1 January 2022GL Capital became a signatory of UNPRI in 2022. As a responsible investor, the firm commits to enhancing ESG performance in daily operations, managing environmental footprint, fostering inclusive workplace, and building greener communities. The firm follows responsible investment and sustainability criteria in investment decisions, seeking to invest in industry-leading companies that contribute to human health and well-being.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Hillhouse Capital: One of the largest Asia-focused asset managers with significant healthcare investments across China. Comparable as a large China-rooted investment platform with healthcare sub-sector focus, though broader in mandate.
• OrbiMed: One of the world's largest healthcare-dedicated investment firms across PE, venture, and royalty strategies. Highly comparable in exclusive healthcare focus and global LP base, though broader geographically.
• CDH Investments: Major China-based PE firm with a healthcare practice alongside diversified sectors. Comparable in China institutional fundraising but broader in mandate than GL Capital's healthcare-only focus.

Direct peers

• Vivo Capital: Healthcare-focused private equity firm with deep China and Asia investment capabilities. Closely comparable in sub-sector coverage (pharma, medical devices, services) and cross-border deal experience.
• Legend Capital (君联资本): China-based PE firm with significant healthcare practice across pharma, medical devices, and services. Comparable in scale, China healthcare specialization, and institutional LP base.
• Loyal Valley Capital: China-focused alternative investment firm with healthcare as a core vertical. Comparable in sub-sector coverage, GP commitment philosophy, and target institutional LP base.
• Quan Capital: Healthcare-focused PE firm investing across China and global markets, with strong pharma/biotech expertise. Directly comparable in exclusive healthcare focus and cross-border deal capability.
• Lake Bleu Capital: Asia healthcare-dedicated public and private investor with PE-style investments across China pharma and devices. Comparable in healthcare-only focus and cross-border sub-sector coverage.
• Bay City Capital: Healthcare-focused PE firm investing globally with significant life sciences orientation. Comparable in exclusive healthcare mandate and long-dated investment approach.
• C-Bridge Capital: Healthcare-dedicated investment platform with strong China and cross-border capabilities. Directly comparable in sub-sector breadth, China healthcare specialization, and institutional LP base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gl-capital-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GL Capital